How a manufacturing business is valued in Australia
A manufacturing business is valued by testing two methods against each other and reconciling the gap: an earnings-based approach — typically an EBITDA multiple or capitalisation of maintainable earnings — and an asset-based approach using the market value of plant and equipment, not its depreciated book value. Both approaches sit under the same professional framework: APES 225 Valuation Services governs how the engagement is scoped and reported, and the market value conclusion itself is assessed consistently with IVS 104, the international standard defining the market value basis. Manufacturing is one of the few sectors where the balance sheet genuinely competes with the profit and loss for attention. A business with a shed full of CNC machines, a paint line and a fleet of forklifts looks substantial, and the instinct is to value the plant and call it the business. The opposite instinct also shows up: an adviser applies a generic "private company" multiple of 3x–4x EBITDA to a manufacturer without asking whether that multiple reflects the sector's capital intensity, customer concentration or energy exposure. Both approaches produce a number. Neither produces a supportable one on its own. A defensible manufacturing valuation reconciles what the plant and equipment is actually worth against what the sustainable earnings are actually worth, and explains why the business trades closer to one than the other.
What EBITDA multiple applies to a manufacturing business
The EBITDA multiple applied to an Australian manufacturing business varies more by subsector, customer concentration and transferability than by revenue size alone — there is no single manufacturing multiple, and no public, transaction-level database of Australian private manufacturing sales exists to derive one from, so any range below is indicative market observation, not a lookup table. Within that limitation, the pattern that shows up consistently in private Australian manufacturing transactions is:
- ·Metal fabrication, general engineering and contract machining — typically the lower end of the range, reflecting high capital intensity, thinner margins and heavy reliance on a small number of commercial or industrial customers
- ·Food and beverage manufacturing with established retail or export listings — generally mid-range, supported by more durable demand and, where relevant, brand or private-label relationships
- ·Building products and construction-linked manufacturing — multiple is highly cyclical; earnings normalisation across a full building cycle matters more here than in most subsectors
- ·Specialised or niche manufacturing with proprietary processes, certifications (e.g. AS/NZS, ISO, medical or defence-grade approvals) or genuine IP — can support multiples toward the higher end where the certification or process is a real barrier to entry, not just a compliance cost
- ·Pure contract/toll manufacturing with one or two dominant customers and no proprietary product — sits at the bottom of any reasonable range regardless of current profitability, because the earnings are not the manufacturer's to keep if the contract moves
Plant and equipment value versus earnings value — the reconciliation
A defensible manufacturing valuation runs both the earnings approach and the asset approach as parallel checks and explains the gap between them, rather than adopting whichever number is higher or lower. The earnings approach — capitalisation of maintainable earnings or an EBITDA multiple — values the business as a going concern generating a return on the capital employed in it. The asset approach — net asset value, informed by an independent plant and equipment valuation where the plant is material — values what the tangible assets would realise. Where the earnings value sits comfortably above net asset value, the business is generating a genuine return on the plant employed and the earnings-based conclusion is usually the more supportable position, with NAV serving as a floor and a cross-check. Where net asset value sits at or above the earnings value, that is a signal worth investigating rather than ignoring: it can mean the plant is genuinely under-earning relative to its replacement cost (a business worth more broken up or sold as equipment than as a going concern), or it can mean maintainable earnings have been understated because normalisation has not properly addressed one-off capex years, COVID-era distortions still sitting in the trailing figures, or owner-operator inefficiencies that a new operator would correct. Both explanations are legitimate. The valuation has to say which one applies and why, not silently pick the higher number.
Do surplus assets get added to a manufacturing valuation
Surplus assets are valued separately from the operating business and added to it, not folded into the earnings-based figure — treating every asset on the fixed asset register as part of the operating business is a common source of overvaluation. Land held for future expansion but not currently used in production, a second shed leased to an unrelated tenant, decommissioned equipment awaiting sale, or a company-owned property with no arm's-length rent charged to the trading entity are all surplus to the earnings the multiple is capitalising. The correct treatment is to value the going-concern operation on the earnings actually produced by the assets in use, then add the market value of surplus assets separately, net of any associated liability or disposal cost. Combining the two into one blended figure — capitalising earnings and then adding the full asset register on top — double-counts value the business does not actually generate and is one of the more common defects we see in valuations prepared without a manufacturing-specific lens.
Why capacity utilisation and the capex cycle affect the number
Trailing EBITDA in a capital-intensive manufacturing business can be genuinely misleading unless it is read against where the plant sits in its capacity cycle, because both a low-utilisation plant and a plant running near practical capacity carry earnings signals a single EBITDA figure does not show. A manufacturer running well below full capacity with an ageing asset base has embedded upside or embedded capex risk that trailing earnings alone will not reveal. A manufacturer running near practical capacity has less organic growth available without further capital investment, which affects both the multiple applied and any forecast used to test the conclusion. Similarly, a business that has just completed a major capex cycle — new plant, automation, a compliance-driven upgrade — will show depressed near-term EBITDA relative to its sustainable earning capacity, while a business that has deferred maintenance capex to flatter recent EBITDA is overstating maintainable earnings. Normalisation needs to look at capital expenditure over a full cycle (typically the plant's useful life, not just the valuation period) and adjust reported EBITDA for maintenance capex that has been deferred or pulled forward, rather than accepting the most recent year's figures at face value.
Customer concentration and supply-contract quality
Customer concentration typically lowers a manufacturing valuation more than it lowers a services-business valuation, because switching a manufacturing customer often means re-tooling, re-certifying or re-tendering — a real barrier to churn, but one that cuts both ways when a small number of customers hold the relationship. Where a small number of customers represent a large share of revenue, the valuation needs to test: whether supply is under a term contract or purchase order only; whether pricing includes cost pass-through mechanisms for input and energy costs or is fixed; the customer's own concentration risk (a single-customer manufacturer supplying a single-customer retailer carries compounded risk); and how much of the relationship depends on personal ties between the owner and the customer rather than the business itself. High concentration with weak contractual protection typically supports a discount to the multiple otherwise indicated by the subsector range, or a higher risk premium in a capitalisation rate, applied and documented as a specific adjustment rather than folded silently into a lower headline multiple.
Does energy cost exposure reduce a manufacturing valuation
Energy cost exposure can reduce a manufacturing valuation where a business sits on exposed commercial electricity or gas contracts, because that margin risk does not apply to trading businesses with lower energy intensity — but it is a normalisation and forecasting question specific to each business (is current energy cost representative, and is there a hedge or fixed-term contract in place), not something with a single Australia-wide figure that can be quoted with confidence, given how much contract terms and network charges vary by state, distributor and business size. A second, opposite force can move a valuation the other way: government supply-chain resilience and onshoring policy settings have supported renewed interest in domestic manufacturing capacity in several subsectors, particularly food and beverage, medical and critical-minerals-adjacent processing. Where this tailwind is genuinely reflected in a business's order book, tender pipeline or recent contract wins, it can support a forward-looking earnings adjustment — but only where there is evidence of it in the numbers, not as a generic narrative applied because the sector is in the news.
Does a manufacturing valuation affect small business CGT concession eligibility
A manufacturing valuation can decide small business CGT concession eligibility outright, because plant, equipment and factory premises push many otherwise modest manufacturers close to the $6m maximum net asset value threshold that gates the 15-year exemption, the retirement exemption and the small business rollover under Div 152. Recent reform has separately lifted the turnover gateway for the 50% active asset reduction to $10m aggregated turnover as an alternative to the $6m net asset test, so which threshold actually applies depends on which concession is being claimed and should be confirmed against current ATO guidance at the time of the engagement, not assumed from a single figure. Where a claim sits near the relevant boundary, the treatment of plant — market value, not depreciated book value, consistent with the ATO's published market valuation guidance for tax purposes — and the treatment of any surplus property or equipment held in the entity or a connected entity becomes central to the outcome, not a formality. This is one of the clearest cases where a desktop estimate is the wrong tool: an under- or over-stated plant value can change eligibility outright, and the file needs to show the methodology and evidence behind the plant figure, not just a number carried over from the depreciation schedule. Prismi is not a registered tax agent and does not provide tax, legal or financial advice; confirmation that a specific Division 152 concession applies to the client's facts is a matter for the client's accountant or lawyer, working from the valuation evidence.
What a manufacturing business valuation costs at Prismi
For most trading manufacturers, the Comprehensive engagement (from $3,995 + GST, 15–25 business days) is the right starting point — it tests earnings-based and asset-based methodologies side by side, which is the reconciliation this sector specifically needs. Where the plant and equipment is material relative to earnings, an independent plant and equipment valuation is typically commissioned alongside the business valuation to support the asset-based cross-check with genuine evidence rather than book value. Where the matter concerns a small business CGT concession claim near the net asset value threshold, a related-party transfer, or a business where customer concentration or capacity utilisation make the conclusion genuinely contestable, the Defensible Valuation File (from $8,995 + GST, 25–35 business days) or, for complex adviser-led matters where the range itself needs to be documented, the Valuation Range & Scenario Review (from $12,995 + GST, 30–45 business days) is the appropriate tier. We do not adopt a plant value or an earnings multiple to hit a target outcome — where a client wants a stated figure regardless of what the evidence supports, we will say so and decline the engagement on those terms.